Print

Immunotherapy shows promise in triple-negative breast cancer

https://www.facingourrisk.org/XRAY/immunotherapy-triple-negative-breast-cancer

Full article: https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm633065.htm

THIS INFORMATION HAS BEEN UPDATED on 04/06/19: Based on published research studies, the FDA approved atezolizumab (Tecentriq) used in combination with the chemotherapy drug nab–paclitaxel (Abraxane) for women with locally advanced or metastatic triple-negative breast cancer that cannot be treated surgically and whose tumors are positive for a protein called PD-L1. The FDA also approved a companion diagnostic test called the VENTANA PD-L1 Assay, to identify patients with triple-negative breast cancer who are candidates for this treatment.

Patients diagnosed with triple-negative breast cancer (TNBC) do not have many treatment options. Immunotherapy, a new type of cancer treatment, pushes the body’s natural defense or immune system to fight cancer. A new immunotherapy drug, atezolizumab (Tecentriq) may improve survival for patients with metastatic TNBC. (07/11/17)  

About FORCE

FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.